📄 medicine

Baloxavir and molnupiravir protect against severe influenza A(H5N1) infection in immunosuppressed hamsters

This study demonstrates that baloxavir, high-dose molnupiravir, and combination therapies effectively protect immunosuppressed hamsters against severe A(H5N1) infection by reducing viral burden and preventing neuroinvasion, highlighting their potential as critical treatments for vulnerable populations during a pandemic.

Original authors: Mariana Baz, Andrea Arroyave, Henintsoa Rabezanahary, Ahmed Sahli

Published 2026-07-13

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Mariana Baz, Andrea Arroyave, Henintsoa Rabezanahary, Ahmed Sahli

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine a tiny, super-strong virus called A(H5N1) (a type of bird flu) that has learned to jump into mammals. Now, picture a group of hamsters whose immune systems have been temporarily "turned down" with a special medicine, making them act like humans with weakened defenses. In this story, the virus is a relentless burglar trying to break into a house with no security guards.

The Burglar's Attack
When the researchers let this virus loose in the immunosuppressed hamsters, the burglar didn't just knock on the door; it kicked it down. The virus caused a severe infection, multiplying wildly in the nose and lungs, and even sneaking into the hamsters' brains. The result was scary: three out of every four hamsters (75%) didn't survive the attack. The virus also stayed in their bodies for a long time, shedding like a constant leak.

However, there was a twist the researchers discovered: even though the infected hamsters were coughing and shedding virus, they couldn't pass it to their healthy friends living in the same cage. The virus was a master burglar inside the house, but it couldn't break out to the neighborhood. It needed a specific set of keys (mutations) to spread between mammals, and this particular strain didn't have them yet.

The Heroes Arrive: The Antiviral Tools
The scientists then tested five different "security systems" (antiviral drugs) to see if they could stop the burglar. They started the treatment 24 hours after the virus arrived and kept it up for five days.

The Old Guard (Oseltamivir): This is a classic drug often used for flu. In this study, it was like a rusty lock. It didn't stop the virus very well. The hamsters treated with this drug still got very sick, lost a lot of weight, and many died. The virus kept replicating in their lungs and brains.
The Low-Powered Shield (Low-dose Molnupiravir): This drug, when given in a small amount, was also like a weak shield. It didn't do much on its own to stop the virus or save the hamsters.
The Super-Strong Force (Baloxavir): This drug was the real MVP. It acted like a high-tech force field. When the hamsters got this treatment, 100% of them survived. The drug stopped the virus from multiplying, cleared it out of the lungs, and most importantly, it blocked the virus from ever reaching the brain. The hamsters barely lost any weight and stayed healthy.
The Heavy Hitter (High-dose Molnupiravir): When the scientists cranked up the dose of the second drug, it became a powerful weapon. Just like Baloxavir, it saved 100% of the hamsters. It cleared the virus from the lungs and the brain, stopping the infection in its tracks.
The Team-Up (Oseltamivir + Low-dose Molnupiravir): When they combined the old guard with the low-dose shield, the result was better than using either alone. It helped control the virus a bit more and reduced the weight loss, but it wasn't as perfect as the heavy hitters.

What the Scientists Are Sure About
The researchers were very careful to check if the virus was learning to cheat the drugs. They looked for specific "cheat codes" (mutations) that usually make viruses resistant to these medicines. They found zero evidence that the virus had changed to become resistant. The drugs failed not because the virus outsmarted them, but because the dose or the type of drug just wasn't strong enough for this specific, severe infection in a weak host.

The Bottom Line
This study shows that for immunosuppressed hosts, the standard flu drug (Oseltamivir) might not be enough against this severe bird flu strain. However, the paper suggests that Baloxavir and high-dose Molnupiravir are incredibly effective, acting like a total shield that prevents death and stops the virus from spreading to the brain. While the combination of drugs showed promise, the single heavy-hitting drugs were the clear winners in this specific simulation.

The authors emphasize that these results come from a specific animal model (hamsters with suppressed immune systems) and suggest that these drug strategies could be vital for protecting vulnerable people in the real world, but they are still in the stage of proving the concept in the lab.

Technical Summary: Baloxavir and Molnupiravir Protect Against Severe Influenza A(H5N1) Infection in Immunosuppressed Hamsters

Problem Statement
Highly pathogenic avian influenza A(H5N1) viruses, particularly the expanding clade 2.3.4.4b genotype D1.1, pose a significant zoonotic threat with high mortality rates in humans. Immunocompromised individuals are at elevated risk for severe, prolonged disease due to delayed viral clearance and sustained replication, yet evidence guiding antiviral therapy for this vulnerable population is limited. While neuraminidase inhibitors (e.g., oseltamivir) and polymerase inhibitors (e.g., baloxavir) are approved for clinical use, their efficacy against contemporary H5N1 strains in immunosuppressed hosts remains under-evaluated. Furthermore, the potential for antiviral resistance and the utility of combination therapies or alternative agents like molnupiravir in this specific context require further investigation.

Methodology
The study utilized a cyclophosphamide (CP)-induced immunosuppressed hamster model to mimic the conditions of vulnerable human hosts. CP administration resulted in sustained immunosuppression, characterized by a 59% reduction in total white blood cells and significant depletion of lymphocytes and monocytes.

Virus: A contemporary human-derived A(H5N1) clade 2.3.4.4b genotype D1.1 virus (A/British Columbia/2032/2024) was used.
Infection Model: Hamsters were intranasally inoculated with $10^5$ TCID $_{50}$ of the virus.
Transmission Study: Contact transmission was assessed by cohousing infected immunosuppressed hamsters with naïve immunosuppressed hamsters.
Antiviral Regimens: Infected immunosuppressed hamsters were treated starting 24 hours post-infection (p.i.) for 5 days with one of six regimens:
1. Placebo.
2. Oseltamivir (OSELT): 20 mg/kg orally twice daily (BID).
3. Baloxavir (BXM): 50 mg/kg subcutaneously on days 1 and 3 p.i.
4. Molnupiravir (MOLN) low-dose: 50 mg/kg orally BID.
5. Molnupiravir (MOLN) high-dose: 200 mg/kg orally BID.
6. Combination: Oseltamivir + low-dose Molnupiravir.
Endpoints: Outcomes included weight loss, survival, viral shedding (nasal washes), viral titers in tissues (nasal turbinates, lungs, brain), pulmonary cytokine expression, and neutralizing antibody responses.
Resistance Analysis: Phenotypic susceptibility (neuraminidase inhibition assay) and genotypic analysis (ddPCR and Sanger sequencing) were performed to detect resistance-associated mutations (e.g., NA-H275Y, PA-I38T).

Key Results

Pathogenesis and Transmission: In immunosuppressed hamsters, the H5N1 virus caused severe disease with 75% mortality by days 10–11 p.i., prolonged viral shedding, and neuroinvasion (viral presence in the brain). In contrast, normal hamsters cleared the virus without mortality. Despite high viral loads and prolonged shedding in immunosuppressed hosts, no contact transmission was observed to naïve hamsters.
Clinical Efficacy:
- Baloxavir (BXM): Achieved 100% survival, significantly reduced weight loss, shortened viral shedding (undetectable by day 5 p.i.), suppressed viral replication in the lungs and brain, and prevented neuroinvasion.
- High-dose Molnupiravir: Also achieved 100% survival, attenuated weight loss, and achieved complete viral clearance in the lungs and brain by day 14 p.i.
- Combination Therapy (Oseltamivir + Low-dose Molnupiravir): Resulted in the lowest mean weight loss (3.1%) and improved viral control in tissues compared to monotherapies, though it did not achieve 100% survival (75%).
- Oseltamivir and Low-dose Molnupiravir Monotherapies: Showed limited efficacy, with survival rates of 75% and 50% respectively, and failed to clear viral replication in tissues or prevent neuroinvasion.
Immune Response: Infected normal hamsters developed robust neutralizing antibodies, whereas immunosuppressed hamsters showed minimal or absent seroconversion.
Resistance: No emergence of antiviral resistance was detected. Phenotypic assays showed no significant reduction in oseltamivir susceptibility (IC $_{50}$ fold changes <10), and molecular analyses confirmed the absence of NA-H275Y, PA-I38T, or other resistance-associated substitutions in treated animals.

Significance and Claims
The authors claim that this study demonstrates the high pathogenicity of a contemporary human-derived A(H5N1) virus in immunosuppressed hosts, characterized by severe disease and neuroinvasion. The findings support baloxavir as a highly effective therapeutic option, capable of preventing mortality and viral dissemination to the brain in this vulnerable population. Additionally, the study identifies high-dose molnupiravir and combination regimens (oseltamivir with low-dose molnupiravir) as promising strategies for controlling severe A(H5N1) infection. The authors conclude that these results highlight the therapeutic potential of polymerase-targeting antivirals and support further investigation of dose optimization and combination approaches for pandemic preparedness, particularly for vulnerable populations where standard monotherapies may be insufficient. The study explicitly notes that the lack of pharmacokinetic analysis in the immunosuppressed model is a limitation, but the comparative efficacy data using clinically relevant dosing regimens provides a foundation for prioritizing antiviral strategies.

More like this